A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for

Status Not yet recruiting

Clinical Trial Summary

Clinical Trial Description

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial. For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered. The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06205095
Study type	Interventional
Source	Unity Health Toronto
Contact
Status	Not yet recruiting
Phase	Phase 3
Start date	June 2024
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT03621020` - Clinical Performance Evaluation of T-TAS 01 PL Chip
Recruiting	`NCT04146376` - Von Willebrand Factor in Pregnancy (VIP) Study
Recruiting	`NCT03715673` - Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
Completed	`NCT03875924` - REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL)
Recruiting	`NCT03773159` - Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Recruiting	`NCT04119908` - Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases	N/A
Not yet recruiting	`NCT04106323` - A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt
Active, not recruiting	`NCT03853486` - ATHN 9: Severe VWD Natural History Study
Recruiting	`NCT05776069` - Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease	Phase 1
Recruiting	`NCT04344860` - Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial	Phase 3
Completed	`NCT04053699` - Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Completed	`NCT04052698` - Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD	Phase 3
Recruiting	`NCT04887324` - Real-life Data of Constitutional Von Willebrand Disease in Western France
Not yet recruiting	`NCT05916469` - Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Completed	`NCT03078595` - Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Recruiting	`NCT03327779` - World Bleeding Disorders Registry
Recruiting	`NCT03070912` - Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Completed	`NCT04466878` - Prognostic Value of Implementing VCE on Top in Constitutional VWD-patients With GI-bleeding
Recruiting	`NCT04810702` - Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD — EMPOWER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms